Skip to main content

Advertisement

SpringerLink
Log in

Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

Prior work has shown that higher circulating concentrations of fibroblast growth factor-21 (FGF-21) are associated with an increased likelihood of developing colorectal cancer. We conducted a prospective study to assess the relationship between circulating FGF-21 and odds of developing early neoplastic lesions in the colorectum.

Methods

A total of 94 study participants were included from the ursodeoxycholic acid (UDCA) trial, a phase III, randomized, double-blind, placebo-controlled clinical trial of the effect of 8–10 mg/kg of body weight UDCA vs. placebo. Logistic regression analyses were conducted to evaluate the association between baseline FGF-21 concentrations and odds of developing a metachronous adenoma.

Results

Of the characteristics compared across tertiles of FGF-21 concentrations, including age, race, sex, BMI, and other variables, only a previous personal history of colorectal polyps prior to entry into the UDCA trial was statistically significantly related to FGF-21 levels, with a proportion of 26.7%, 56.7%, and 50.0% across the first, second, and third tertiles, respectively (p < 0.05). Higher circulating concentrations of FGF-21 were statistically significantly associated with greater odds of developing a metachronous colorectal adenoma. After adjusting for potential confounders and when compared with the lowest tertile of FGF-21, the adjusted ORs (95% CIs) for metachronous colorectal adenoma in the second and third tertiles were 4.72 (95% CI, 1.42–15.72) and 3.82 (95% CI, 1.15–12.68), respectively (p trend < 0.05).

Conclusion

Our results reveal for the first time that, in addition to a recently discovered association with colorectal cancer, circulating FGF-21 concentrations are significantly and directly associated with odds of developing metachronous colorectal adenoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Data Availability

The data may be requested from the principal investigator and may be subject to IRB approval.

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.

    Article  Google Scholar 

  2. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.

    Article  Google Scholar 

  3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.

    Article  CAS  Google Scholar 

  4. Lasry A, Zinger A, Ben-Neriah Y. Inflammatory networks underlying colorectal cancer. Nat Immunol. 2016;17(3):230–40.

    Article  CAS  Google Scholar 

  5. Dela Cruz MD, Ledbetter S, Chowdhury S, Tiwari AK, Momi N, Wali RK, et al. Metabolic reprogramming of the premalignant colonic mucosa is an early event in carcinogenesis. Oncotarget. 2017;8(13):20543–57.

    Article  Google Scholar 

  6. Qian J, Tikk K, Weigl K, Balavarca Y, Brenner H. Fibroblast growth factor 21 as a circulating biomarker at various stages of colorectal carcinogenesis. Br J Cancer. 2018;119(11):1374–82.

    Article  CAS  Google Scholar 

  7. Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov. 2016;15:51–69.

    Article  CAS  Google Scholar 

  8. Knott ME, Minatta JN, Roulet L, Gueglio G, Pasik L, Ranuncolo SM, et al. Circulating fibroblast growth factor 21 (Fgf21) as diagnostic and prognostic biomarker in renal cancer. J Mol Biomarker Diag. 2016;1(Suppl 2):015. https://doi.org/10.4172/2155-9929.S2-015.

    Article  Google Scholar 

  9. Knott ME, Ranuncolo SM, Nuñez M, Armanasco E, Puricelli LI, De Lorenzo MS. Levels of fibroblast growth factor 21 (FGF21) in serum as diagnostic biomarker in patients with breast cancer. Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. Cancer Res. 2015;75(15 Suppl):Abstract no.1577. https://doi.org/10.1158/1538-7445.AM2015-1577.

    Article  Google Scholar 

  10. Harlid S, Myte R, Van Guelpen B (2017). The metabolic syndrome, inflammation, and colorectal cancer risk: an evaluation of large panels of plasma protein markers using repeated, prediagnostic samples. Med Inflamm. https://doi.org/10.1155/2017/4803156. Epub 2017 Mar 22.

  11. Alberts DS, Martinez ME, Hess LM, Einspahr JG, Green SB, Bhattacharyya AK, et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst. 2005;97(11):846–53.

    Article  CAS  Google Scholar 

  12. Jess T, Frisch M, Simonsen J. Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. Clin Gastroenterol Hepatol. 2013;11(1):43–8.

    Article  Google Scholar 

  13. Burn J, Gerdes A-M, Macrae F, Mecklin J-P, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011;378(9809):2081–7.

    Article  Google Scholar 

  14. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente A, Bories C, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterol. 1991;101(3):635–9.

    Article  CAS  Google Scholar 

  15. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res. 2010;342(1):1–11.

    Article  CAS  Google Scholar 

  16. Youm Y-H, Horvath TL, Mangelsdorf DJ, Kliewer SA, Dixit VD. Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. PNAS. 2016;113(4):1026–31.

    Article  CAS  Google Scholar 

  17. Hanks LJ, Gutiérrez OM, Bamman MM, Ashraf A, McCormick KL, Casazza K. Circulating levels of fibroblast growth factor-21 increase with age independently of body composition indices among healthy individuals. J Clin Transl. 2015;2(2):77–82.

    Google Scholar 

  18. Amersi F, Agustin M, Ko CY. Colorectal cancer: epidemiology, risk factors, and health services. Clin Colon Rectal Surg. 2005;18(3):133–40. https://doi.org/10.1055/s-2005-916274.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hamoya T, Fujii G, Miyamoto S, Takahashi M, Totsuka Y, Wakabayashi K, et al. Effects of NSAIDs on the risk factors of colorectal cancer: a mini review. Genes Environ. 2016;38:6. https://doi.org/10.1186/s41021-016-0033-0.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;76(9754):1741–50.

    Article  Google Scholar 

  21. Yang C, Lu W, Lin T, You P, Ye M, Huang Y, et al. Activation of liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol. 2013;13(1):67.

    Article  CAS  Google Scholar 

  22. Markan KR, Naber MC, Ameka MK, Anderegg MD, Mangelsdorf DJ, Kliewer SA, et al. Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding. Diabetes. 2014;63(12):4057–63.

    Article  CAS  Google Scholar 

  23. Akyol M, Alacacioglu A, Demir L, Kucukzeybek Y, Yildiz Y, Gumus Z, et al. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. Cancer Biomark. 2017;18(4):441–9.

    Article  CAS  Google Scholar 

  24. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, DeFronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care. 2009;32(8):1542–6.

    Article  CAS  Google Scholar 

  25. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol. 2009;71(3):369–75.

    Article  CAS  Google Scholar 

Download references

Funding

This study was funded by the National Cancer Institute Cancer Center Support (Grant P30CA023074; NIH/NCI RO1CA140285; NIH/NCI; NIH/NCI P01CA041108).

Author information

Authors and Affiliations

  1. Department of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

    Ana Florea, Robin B. Harris, Yann C. Klimentidis, Lindsay N. Kohler & Elizabeth T. Jacobs

  2. Department of Medicine, Division of Nephrology, College of Medicine, University of Arizona, Tucson, AZ, USA

    Ana Florea

  3. Department of Health Promotion Sciences, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, USA

    Lindsay N. Kohler

  4. School of Mathematical and Natural Sciences, Arizona State University, Glendale, AZ, USA

    Peter W. Jurutka

  5. Department of Basic Medical Sciences, University of Arizona College of Medicine, Phoenix, AZ, USA

    Peter W. Jurutka

Authors
  1. Ana Florea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robin B. Harris
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yann C. Klimentidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lindsay N. Kohler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter W. Jurutka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elizabeth T. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Dr. Ana Florea, Dr. Elizabeth Jacobs, and Dr. Peter W. Jurutka were responsible for the design, acquisition of data, and interpretation of data. Dr. Ana Florea and Dr. Elizabeth Jacobs were responsible for data analyses. Dr. Lindsay Kohler, Dr. Robin Harris, and Dr. Yann Klimentidis made substantial contributions to manuscript preparation and interpretation of data. All authors assisted with the drafting and critical revisions of the article by making important intellectual contributions, approved the work to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Ana Florea.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Ethics Approval

This study has been approved by the University of Arizona Institutional Review Board.

Consent to Participate

All participants provided written and signed informed consent forms.

Consent to Publish

All participants provided written and signed informed consent forms.

Code Availability

No special or custom code was used.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Florea, A., Harris, R.B., Klimentidis, Y.C. et al. Circulating Fibroblast Growth Factor-21 and Risk of Metachronous Colorectal Adenoma. J Gastrointest Canc 52, 940–946 (2021). https://doi.org/10.1007/s12029-020-00515-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-020-00515-8

Keywords

Search

Navigation